Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Nathalie A. Kulin, MSc
Advertisement
Articles by Nathalie A. Kulin, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
4
SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF
5